OTUNETY Trademark
Trademark Overview
On Thursday, April 7, 2022, a trademark application was filed for OTUNETY with the United States Patent and Trademark Office. The USPTO has given the OTUNETY trademark a serial number of 97351725. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, June 26, 2024. This trademark is owned by Bristol-Myers Squibb Company. The OTUNETY trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
General Information
| Serial Number | 97351725 |
| Word Mark | OTUNETY |
| Filing Date | Thursday, April 7, 2022 |
| Status | 731 - SECOND EXTENSION - GRANTED |
| Status Date | Wednesday, June 26, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 16, 2023 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 12, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10016 |
Trademark Events
| Event Date | Event Description |
| Monday, April 11, 2022 | NEW APPLICATION ENTERED |
| Tuesday, April 12, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, September 29, 2022 | ASSIGNED TO EXAMINER |
| Friday, October 7, 2022 | NON-FINAL ACTION WRITTEN |
| Friday, October 7, 2022 | NON-FINAL ACTION E-MAILED |
| Friday, October 7, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, April 7, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, April 7, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, April 7, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, April 10, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 26, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 16, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 16, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 11, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, August 2, 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, August 2, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, August 2, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, January 2, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, January 2, 2024 | SOU EXTENSION 1 FILED |
| Tuesday, January 2, 2024 | SOU EXTENSION 1 GRANTED |
| Thursday, January 4, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, June 26, 2024 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, June 26, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, June 26, 2024 | SOU EXTENSION 2 FILED |
| Wednesday, June 26, 2024 | SOU EXTENSION 2 GRANTED |
| Wednesday, December 11, 2024 | SOU TEAS EXTENSION RECEIVED |
